Signaling pathways responsible for cancer cell invasion as targets for cancer therapy

Current Cancer Drug Targets

Volumn 4, Issue 4, 2004, Pages 327-336

  Sliva, Daniel ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Cancer invasion and metastasis; NF B; Signaling pathways; uPA; uPAR

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER THERAPY; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; METASTASIS; PROTEIN DEGRADATION; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NF-KAPPA B; PROTEIN KINASE C; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 2942717090     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043332961     Document Type: Review

References (119)

1. Price, J. T.; Bonovich, M. T.; Kohn, E. C. The biochemistry of cancer dissemination. Crit. Rev. Biochem. Mol. Biol. 1997, 32, 175-253.
2. Symes, K.; Mercola, M. Embryonic mesoderm cells spread in response to platelet-derived growth factor and signaling by phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 9641-9644.
3. Henke, C. A.; Roongta, U.; Mickelson, D. J.; Knutson, J. R.; McCarthy, J. B. CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J. Clin. Invest. 1996, 97, 2541-2542.
4. Camussi, G.; Monstrucchio, G.; Lupia, E.; Soldi, R.; Comoglio, P. M.; Bussolino, F. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. J. Immunol. 1997, 158, 1302-1309.
5. Yu, A. E.; Hewitt, R. E.; Connor, E. W.; Stetler-Stevenson, W. G. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 1997, 11, 229-244.
6. Chapman, H. A.; Riese, R. J.; Shi, G. P. Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol. 1997, 59, 63-88.
7. Andreasen, P. A., Kjøller, L.; Christensen, L.; Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72, 1-22.
8. Blasi, F. uPA, uPAR, PAI-1: A key intersection in proteolysis, adhesion and chemotaxis highways? Immunol. Today 1997, 18, 415-417.
9. Sheela, S.; Barrett, J. C. Degradation of type IV collagen by neoplastic human skin fibroblasts. Carcinogenesis 1982, 3, 363-369.
10. Danø, K.; Andreasen, P. A.; Grondahl-Hansen, J.; Kristensen, P.; Nielsen, L. S.; Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 1985, 44, 139-266.
11. Murphy, G.; Willenbrock, F.; Crabbe, T.; O'Shea, M.; Ward, R.; Atkinson, S.; O'Connell, J.; Docherty, A. Regulation of matrix metalloproteinase activity. Ann. N. Y. Acad Sci. 1994, 732, 31-41.
12. Schmitt, M.; Janicke, F.; Moniwa, N.; Chuckolowski, N.; Pache, L.; Graeff, H. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe-Seyler 1992, 373, 611-622.
13. Sidenius, N.; Andolfo, A.; Fesce, R.; Blasi, F. Urokinase regulates vitronectin binding in vitro and in vivo by controlling urokinase receptor oligomerization. J. Biol. Chem. 2002, 277, 27982-27990.
14. Blasi, F.; Carmeliet, P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 2002, 3, 932-943
15. Kjøller, L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol. Chem. 2002, 383, 5-19
16. Yebra, M.; Parry, G. C.; Stromblad, S.; Mackman, N.; Rosenberg, S.; Mueller, B. M.; Cheresh, D. A. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J. Biol. Chem. 1996, 271, 29393-29399.
17. Degryse, B.; Orlando, S.; Resnati, M.; Rabbani, S. A.; Blasi, F. Urokinase/urokinase receptor and vitronectin/αvβ3 integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 2001, 20, 2032-2043.
18. Mazar, A. P. The urokinase plasminogen activator receptor (upar) as a target for the diagnosis and therapy of cancer. Anti-Cancer Drugs 2001, 12, 387-400.
19. Nerlov, C.; Rorth, P.; Blasi, F.; Johnsen, M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991, 6, 1583-1593.
20. Lengyel, E.; Gum, R.; Stepp, E.; Juarez, J.; Wang, H.; Boyd, D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J. Cell. Biochem. 1996, 61, 430-438.
21. Wang, Y. The Role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res. Rev. 2001, 21, 146-170.
22. Mori, N.; Fujii, M.; Iwai, K.; Ikeda, S.; Yamasaki, Y.; Hata, T.; Yamasa, Y.; Tanaka, Y.; Tomonaga, M.; Yamamoto, N. Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells. Blood 2000, 95, 3915-3921.
23. Mathas, S.; Hinz, M.; Anagnostopoulos, I.; Krappmann, Lietz, A.; Jundt, F.; Bommert, K.; Mechta-Grigoriou, F.; Stein, H.; Dörken, B.; Scheidereit, C. Abberantly expressed C-Jun and Jun B are a hallmark of hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB. EMBO J. 2002, 21, 4104-4113.
24. Nakshatri, H.; Bhat-Nakshatri, P.; Martin, D. A.; Goulet, R. J. Jr.; Sledge, G. W. Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 1997, 17, 3629-3639.
25. Mukhopadhyay, A.; Bueso-Ramos, C.; Chatterjee, D.; Pantazis, P.; Aggarwal, B. B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001, 20, 7597-7609.
26. Ondrey, F. G.; Dong, G.; Sunwoo, J.; Chen, Z.; Wolf, J. S.; Crowl-Bancroft, C.; V.; Mukaida, N.; Van Waes, C. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol. Carcinog. 1999, 26, 119-129.
27. Thakur, S.; Lin, H. C.; Tseng, W. T.; Kumar, S.; Bravo, R.; Foss, F.; Gelinas, C.; Rabson, A. B. Rearrangements and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene 1994, 9, 2335-2344.
28. Cabannes, E.; Khan, G.; Aillet, F.; Jarrett, R. F.; Hay, R. T. Mutations in the IκBα gene in Hodgkin's disease suggest a tumor suppressor role for IκB. Oncogene 1999, 18, 23063-3070.
29. Krappmann, D.; Emmerich, F.; Kordes, U.; Scharschmidt, E.; Dörken, B.; Scheidereit, C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999, 18, 943-953.
30. Wang, W.; Abbruzzese, J. L.; Evans, D. B.; Larry, L.; Karen, R.; Cleary, K. R.; Chiao, P. J. The nuclear Factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 1999, 5, 119-127.
31. Tai, D. I.; Tsai, S. L.; Chang, Y. H.; Huang, S. N.; Chen, T. C.; Chang, K. S.; Liaw, Y. F. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 2000, 89, 2274-3381.
32. Ludwig, L.; Kessler, H.; Wagner, M.; Hoang-Vu, C.; Dralle, H.; Adler, G.; Böhm, B. O.; Schmidt, R. M. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res. 2001, 61, 4526-4535.
33. Sovak, M. A.; Bellas, R. E.; Kim, D. W.; Zanieski, G. J.; Rogers, A. E.; Traish, A. M.; Sonenshein, G. E. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 1997, 100, 2952-2960.
34. Suh, J.; Payvandi, F.; Edelstein, L. C., Amenta, P. S.; Zong, W.-X.; Gelinas, C.; Rabson, A. B. Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 2002, 52, 183-200.
35. Le, X.; Shi, Q.; Wang, B.; Xiong, Q.; Qian, C.; Peng, Z.; Li, X. C.; Tang, H.; Abbruzzese, J. L.; Xie, K. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J. Interferon Cytokine Res. 2000, 20, 935-946.
36. Stein, B.; Baldwin, A. S. Jr.; Ballard, D. W.; Greene, W. C.; Angel, P.; Herrlich, P. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 1993, 12, 3879-3891.
37. Banerjee, S.; Bueso-Ramos, C.; Aggarwal. B. B. Suppression of 7, 12-dimethylbenz(a)-anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 2002, 62, 4945-4954.
38. Diehl, J. A. Cycling to cancer with cyclin D1. Cancer Biol. Ther. 2002, 1, 226-231.
39. Schorr, K.; Li, M.; Krajewski, S.; Reed, J. C.; Furth, P. A. Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J. Mam. Gland Biol. Neoplasia 1999, 4, 153-164.
40. Shibata, A.; Nagaya, T.; Imai, T.; Funahashi, H.; Nakao, A.; Seo, H. Inhibition of NF-κB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat. 2002, 73, 237-243.
41. Wang, C. Y.; Cusack, J. C. Jr.; Liu, R.; Baldwin, A. S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Med. 1999, 5, 412-417.
42. Orlowski, R. Z.; Baldwin, A. S. Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 2002, 8, 385-389.
43. Orlowski, R. Z.; Stinchcombe, T. E.; Mitchell, B. S.; Shea, T. C.; Baldwin, A. S.; Stahl, S.; Adams, J.; Esseltine, D-L.; Elliot, P. J.; Pien, C. S.; Guerciolini, R.; Anderson, J. K.; Depcik-Smith, N. D.; Bhagat, R.; Lehman, M. J.; Novick, S. C.; O'Connor, O. A.; Soignet, S. L. Phase I trial of the proteosome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002, 20, 4420-4427.
44. Baldwin, A. S. The NF-κB and IκB: new discoveries and insights. Annu. Rev. Immunol. 1996, 14, 649-683.
45. Ghosh, S.; May, M. J.; Kopp, E. B. NF-κB and Rel proteins: evolutionary conserved mediators of immune responses. Annu. Rev. Immunol. 1998, 16, 225-260.
46. Karin, M. The beginning of the end: IκB kinase (IKK) and NF-κB activation. J. Biol. Chem. 1999, 274, 27339-27342.
47. Sakurai, H.; Chiba, H.; Miyoshi, H.; Sugita, T.; Toriumi, W. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 1999, 274, 30353-30356.
48. Sizemore, N.; Lerner, N.; Dombrowski, N.; Sakurai, H.; Stark, G. R. Distinct roles of the IκB kinase α and β subunits in liberatmg liberating nuclear factor κB (NF-κB) from IκB and phosphorylating the p65 subunit of NF-κB. J. Biol. Chem. 2002, 277, 3863-3869.
49. Bird, T. A.; Schooley, K.; Dower, S. K.; Hagen, H.; Virca, G. D. Activation of nuclear transcription factor NF-κB by interleukin-1 is accompanied by casein kinase-imediated phosphorylation of the p65 subunit. J. Biol. Chem. 1997, 272, 32606-32612.
50. Romieu-Mourez, R.; Landesman-Bollag, E.; Seldin, D. C.; Sonenshein, G. E. Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 2002, 62, 6770-6778.
51. Zhong, H.; Voll, R.; Ghosh, S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the co-activator CBP/p300. Mol. Cell 1998, 1, 661-671.
52. Sizemore, N.; Larner, N.; Dombrowski, N.; Sakurai, H.; Stark, G. R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of NF-κB p65/rela subunit. Mol. Cell. Biol. 1999, 19, 4798-4805.
53. Martin, A. G.; San-Antonio, B.; Fresno, M. Regulation of nuclear factor κB transactivation. J. Biol. Chem. 2001, 276, 15840-15849.
54. ras and protein kinase Cζ in primary endothelial cells. J. Biol. Chem. 1999, 274, 13594-13603.
55. Carter, A. B.; Knudston, K. L.; Monick, M. M.; Hunninghake, G. W. The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression. J. Biol. Chem. 1999, 274, 30858-30863.
56. Sliva, D.; Mason, R.; Xiao, H.; English, D. Enhancement of the migration of human breast cancer cells by phosphatidic acid. Biochem. Biophys. Res. Commun. 2000, 268, 471-479.
57. Derman, M. P.; Toker, A.; Hartwig, J. H.; Spokes, K.; Falck, J. R.; Chen, C.-S.; Cantley, L. C.; Cantley, L. G. The lipid products of phosphoinositide 3-kinase increase cell motility through protein kinase C. J. Biol. Chem. 1997, 272, 6465-6470.
58. Sliva, D.; Rizzo, M. T.; English, D. Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator (uPA). J. Biol. Chem. 2002, 277, 3150-3157.
59. Domin, J.; Waterfield, M. D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 1997, 410, 91-95.
60. Suzuki, H.; Terauchi, Y.; Fujiwara, M.; Aizawa, S.; Yazaki, Y.; Kadowaki, T.; Koyasu, S. Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase. Science 1999, 283, 390-392.
61. Fruman, D. A.; Snapper, S. B.; Yballe, C. M.; Davidson, L.; Yu, J. Y.; Alt, F. W.; Cantley, L. C. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 1999, 283, 393-397.
62. Vanhaesebroeck, B.; Jones, G. E.; Allen, W. E.; Zicha, D.; Hooshmand-Rad, R.; Sawyer, C.; Wells, C.; Waterfield, M. D.; Ridley, A. J. Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nature Cell Biol. 1999, 1, 69-71.
63. Sasaki, T.; Irie-Sasaki, J.; Jones, R. G.; Oliviera-dos-Santos, A. J.; Stanford, W. L.; Bolon, B.; Wakeham, A.; Itie, A.; Bouchard, D.; Kozieradzki, I.; Joza, N.; Mak, T. W.; Ohashi, P. S.; Suzuki, A.; Penninger, J. M. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 2000, 287, 1040-1046.
64. Li, Z.; Jiang, H.; Xie, W.; Zhang, Z.; Smrcka, A. V.; Wu, D. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 2000, 287, 1046-1049.
65. Hirsch, E.; Katanaev, V. L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.; Altruda, F.; Wymann, M. P. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 2000, 287, 1049-1053.
66. Beraud, C.; Henzel, W. J.; Baeuerle, P. A. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-κB activation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 429-434.
67. Mellor, H.; Parker, P. J. The extended protein kinase C superfamily. Biochem J. 1998, 332, 281-292.
68. O'Brian, C. A.; Vogel, V. G.; Singletary, S. E.; Ward, N. E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. 1989, 49, 3215-3217.
69. Gordge, P. C.; Hulme, M. J.; Clegg, R. A.; Miller, W. R. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur. J. Cancer 1996, 32A, 2120-2126.
70. Morse-Gaudio, M.; Connolly, J. M.; Rose, D. P. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int. J. Oncol. 1998, 12, 1349-1354.
71. Ways, D. K.; Kukoly, C. A.; De Vente, J.; Hooker, J. L.; Bryant, W. O.; Posekany, K. J.; Fletcher, D. J.; Cook, P. P.; Parker, P. J. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. 1995, 95, 1906-1915.
72. Johnson, M. D.; Torri, J. A.; Lippman, M. E.; Dickson, R. B. Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness. Exp. Cell Res. 1999, 247, 105-113.
73. Sliva, D.; English, D.; Lyons, D.; Lloyd, F. P. Jr. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator (uPA) through the activation of AP-1 and NF-κB. Biochem. Biophys. Res. Commun. 2002, 290, 552-557.
74. Martiny-Baron, G.; Kazanietz, M. G.; Mischak, H.; Blumberg, P. M.; Kochs, G.; Hug, H.; Marme, D.; Schachtele, C. Selective inhibition of protein kinase C isozymes by the indolocarbazole GO 6976. J. Biol. Chem. 1993, 268, 9194-9197.
75. Biswas, D. K.; Cruz, A. P.; Gansberger, E.; Pardee, A. B. Epidermal growth factor-induced nuclear factor κB activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8542-8547.
76. Cobb, M. H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 1999, 71, 479-500.
77. Santen, R. J.; Song, R. X.; McPherson, R.; Kumar, R.; Adam, L.; Jeng, M-H.; Yue, W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 2002, 80, 239-256.
78. Witowski, J.; Abell, A.; Johnson, N. L.; Johnson, G. L.; Cuevas, B. D. MEKK1 is required for inducible urokinase-type plasminogen activator expression. J. Biol. Chem. 2003, 278, 5941-5946.
79. Huang, S.; New, L.; Pan, Z.; Han, J; Nemerow, G. R. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38α mitogen-activated protein kinase activity. J. Biol. Chem. 2000, 275, 12266-12272.
80. Seddighzadeh, M.; Zhou, J-N.; Kronenwett, U.; Shoshan, M. C.; Auer, G.; Sten-Linder, M.; Wiman, B.; Linder, S. ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin. Exp. Metastasis 1999, 17, 649-654.
81. Karin, M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 1995, 270, 16483-16486.
82. Adderley, S. R.; Fitzgerald, D. J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J. Biol. Chem. 1999, 274, 5038-5046.
83. Stern, D. F. Tyrosine kinase signaling in breast cancer: erbb family receptor tyrosine kinases. Breast Cancer Res. 2002, 2, 176-183.
84. Ryan, P. D.; Chabner, B. A. On Receptor inhibitors and chemotherapy. Clin. Cancer Res. 2000, 6, 4607-4609.
85. Klijn, J. G.; Look, M. P.; Portengen, H.; Alexieva-Figusch, J.; van Putten, W. L.; Foekens, J. A. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res. Treat. 1994, 29, 73-83.
86. McCawley, L. J.; O'Brien, P.; Hudson, L. G. Overexpression of the epidermal growth factor receptor contributes to enhanced ligand-mediated motility in keratinocyte cell line. Endocrinology 1997, 138, 121-127.
87. Wang, F.; Weaver, V. M.; Petersen, O. W.; Larabell, C. A.; Dedhar, S.; Briand, P.; Lupu, R.; Bissell, M. J. Reciprocal interaction between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultured: a different perspective in epithelial biology. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 14821-14826.
88. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61, 1-13.
89. Mazumdar, S.; Adam, L.; Boyd, D.; Kumar, R. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res. 2001, 61, 400-405.
90. Tsai, M-S.; Shamon-Taylor, L. A.; Mehmi, I.; Tang, C. K.; Lupu, R. Blockade of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003, 22, 761-768.
91. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001, 7, 2958-2970.
92. Wells, A. Molecules in focus EGF receptor. Int. J. Biochem. Cell Biol. 1999, 31, 637-643.
93. Cobleigh, M. A.; Vogel, C. L.; Tripathy, D.; Robert, N. J.; Scholl, S.; Fehrenbacher, L.; Wolter, J. M.; Paton, V.; Shak, S.; Lieberman, G.; Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17, 2639-2648.
94. Johnston, S. R. D.; Head, J.; Pancholi, S.; Detre, S.; Martin, L-A.; Smith, I. A.; Dowsett, M. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin. Cancer Res. 2003, 9, 524s-532s.
95. Li, M.; Ye, C.; Feng, C.; Riedel, F.; Liu, X.; Zeng, Q.; Grandis, J. R. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin. Cancer Res. 2002, 8, 3570-3578.
96. Ciardiello, F.; Tortora, G. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin. Cancer Res. 1998, 4, 821-828.
97. Tortora, G.; Ciardiello, F. Protein kinase A as a target for novel integrated strategies of cancer therapy. Ann. N. Y. Acad. Sci. 2002, 968, 139-147.
98. Geschner, A. Analogs of staurosporine: potential anticancer drugs? Gen. Pharm. 1998, 31, 721-728.
99. Hofmann, J. Modulation of protein kinase C in antitumor treatment. Rev. Physiol. Biochem. Pharmacol. 2001, 142, 1-96.
100. Sausville, E. A.; Arbuck, S. G.; Messmann, R.; Headlee, D.; Bauer, K. S.; Lush, R. M.; Murgo, A.; Figg, W. D.; Lahusen, T.; Jaken, S.; Jing, X.; Roberge, M.; Fuse, E.; Kuwabara, T.; Senderowicz, A. M. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 2001, 19, 2319-2333.
101. Mani, S.; Rudin, C. M.; Kunkel, K.; Holmlund, J. T.; Geary, R. S.; Kindler, H. L.; Dorr, F. A.; Ratain, M. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin. Cancer Res. 2002, 8, 1042-1048.
102. Cripps, M. C.; Figueredo, A. T.; Oza, A. M.; Taylor, M. J.; Fields, A. L.; Holmlund, J. T.; McIntosh, L. W.; Geary, R. S.; Eisenhauer, E. A. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Clin. Cancer Res. 2002, 8, 2188-2192.
103. Tolcher, A. W.; Reyno, L.; Venner, P. M.; Ernst, S. D.; Moore, M.; Geary, R. S.; Chi, K.; Hall, S.; Walsh, W.; Dorr, A.; Eisenhauer, E. A Randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2002, 8, 607-614.
104. Swannie, H. C.; Kaye, S. B. Protein kinase C inhibitors. Curr. Oncol. Rep. 2002, 4, 37-46.
105. Brognard, J.; Clark, A. S.; Ni, Y.; Dennis, P. A. Akt/protein kinase B is constitutively active in non-small call lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61, 3986-3997.
106. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1, 707-717.
107. Semba, S.; Itoh, N.; Ito, M.; Harada, M.; Yamakawa, M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phospatidylinositol 3′-kinase, in human colon cancer cells. Clin. Cancer Res. 2002, 8, 1957-1966.
108. Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000, 19, 6594-6599.
109. Hilger, R. A.; Scheulen, M. E.; Strumberg, D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002, 25, 511-518.
110. Magnani, M.; Crinelli, R.; Bianchi, M.; Antonelli, A. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-κB (NF-κB). Curr. Drug Targets 2000, 1, 387-399.
111. Adams, J. Development of the proteasome inhibitor PS-341. The Oncologist. 2002, 7, 9-16.
112. Wilhelm, O.; Schmitt, M.; Hohl, S.; Senekowitsch, R.; Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. Exp. Metastasis 1995, 13, 296-302.
113. Mohanam, S.; Jasti, S. L.; Kondraganti, S. R.; Chanrasekar, N.; Kin, Y.; Fuller, G. N.; Lakka, S. S.; Kyritsis, A. P.; Dinh, D. H.; Olivero, W. C.; Gujrati, M.; Yung, W. K. A. Yung, Rao, J. S. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin. Cancer Res. 2001, 7, 2519-2526.
114. Rabbani, S. A.; Harakidas, P.; Davidson, D. J.; Henkin, J.; Mazar, A. P. Prevention of prostate cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer 1995, 63, 840-845.
115. Mohan, P. M.; Chintala, S. K.; Mohanam, S.; Gladson, C. L.; Kim, E. S.; Lakka, S. S.; Roth, J. A.; Fang, B.; Kyritsis, A. P.; Rao, J. S. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor (uPAR) suppresses glioma invasion and tumor growth. Cancer Res. 1999, 59, 3369-3373.
116. Lakka, S. S.; Rajagopal, R.; Rajan, M. K.; Mohan, P. M.; Adachi, Y.; Dinh, D. H.; Olivero, W. C.; Gujrati, M.; Ali-Osman, F.; Roth, J. A.; Yung, W. K. A.; Kyritsis, A. P.; Rao, J. S. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines. Clin. Cancer Res. 2001, 7, 1087-1093.
117. Ossowski, L.; Russo-Payne, H.; Wilson, E. L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 1991, 51, 274-281.
118. Guo, Y.; Higazi, A. A-R.; Arakelian, A.; Sachais, B. S.; Cines, D.; Goldfarb, R. H.; Jones, T. R.; Kwaan, H.; Mazae, A. P.; Rabbani, S. A. A Peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 2000, 14, 1400-1410.
119. Rabbani, S. A.; Gladu, J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 2002, 62, 2390-2397.